Back to Results
First PageMeta Content
Overactive bladder / Muscarinic antagonists / Astellas Pharma / Solifenacin / Urinary incontinence / Frequent urination / Urge incontinence / Urination / Percutaneous tibial nerve stimulation / Medicine / Urology / Incontinence


June 18, 2010 Application for Mirabegron (YM178), a Treatment for OAB, in Japan Tokyo, Japan, June 18, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced th
Add to Reading List

Document Date: 2010-06-17 22:05:31

Open Document

File Size: 41,04 KB

Share Result on Facebook

City

Tokyo / /

Company

Astellas Pharma Inc. / /

Continent

Asia / Europe / /

Country

Taiwan / Korea / China / Japan / United States / India / /

Event

FDA Phase / /

/

MedicalCondition

overactive bladder / urge incontinence / urinary incontinence / /

Organization

Neurogenic Bladder Society / Pharmaceuticals and Medical Devices Agency / /

Person

Masafumi Nogimori / /

/

Position

President and CEO / /

Product

Vesicare / China / Japan / /

URL

http /

SocialTag